John Lowe

8.2k total citations · 1 hit paper
143 papers, 6.0k citations indexed

About

John Lowe is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, John Lowe has authored 143 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 51 papers in Cellular and Molecular Neuroscience and 18 papers in Pharmacology. Recurrent topics in John Lowe's work include Neuropeptides and Animal Physiology (30 papers), Receptor Mechanisms and Signaling (27 papers) and Chemical Synthesis and Analysis (13 papers). John Lowe is often cited by papers focused on Neuropeptides and Animal Physiology (30 papers), Receptor Mechanisms and Signaling (27 papers) and Chemical Synthesis and Analysis (13 papers). John Lowe collaborates with scholars based in United States, United Kingdom and Australia. John Lowe's co-authors include Billy R. Martin, R. Michael Snider, Mario D. Aceto, Joseph G. Lombardino, Susan E. Drozda, Sandra P. Welch, Kelly P. Longo, David M. Compton, Fredric J. Vinick and Heidi A. Woody and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

John Lowe

135 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Potent Nonpeptide Antagonist of the Substance P (NK ₁ ) Receptor

1991 727 citations R. Michael Snider, John Lowe et al. profile →

Peers

Countries citing papers authored by John Lowe

Since Specialization

Citations

This map shows the geographic impact of John Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Lowe more than expected).

Fields of papers citing papers by John Lowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Lowe. The network helps show where John Lowe may publish in the future.

Co-authorship network of co-authors of John Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of John Lowe. A scholar is included among the top collaborators of John Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Lowe. John Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial 2014 ·The AAPS Journal ·Kelong Han, (unknown), Mauricio Maia, John Lowe, Martina Sersch, David E. Allison	40
2	A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life 2010 ·Cancer Research ·Yik A. Yeung, Xiumin Wu, Arthur E. Reyes, Jean-Michel Vernes, Samantha Lien, John Lowe, Mauricio Maia, William F. Forrest, Y. Gloria Meng, Lisa A. Damico, Napoleone Ferrara, Henry B. Lowman	56
3	The absence of endogenous β-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation 2007 ·Neuroscience ·(unknown), Shuang Li, Terri L. Gilbert, R. Westenbroek, Michael R. Bruchas, Shaul Schreiber, John Lowe, Malcolm J. Low, John E. Pintar, Charles Chavkin	58
4	Transitional B Cell Fate Is Associated with Developmental Stage-Specific Regulation of Diacylglycerol and Calcium Signaling upon B Cell Receptor Engagement 2006 ·The Journal of Immunology ·Kristen L. Hoek, Pierre Antony, John Lowe, Nicholas Shinners, (unknown), Susan R. Wente, Demin Wang, Rachel M. Gerstein, Wasif N. Khan	33
5	The role of the medicinal chemist in drug discovery — then and now 2004 ·Nature Reviews Drug Discovery ·Joseph G. Lombardino, John Lowe	249
6	Glycine transporter type 1 blockade changes NMDA receptor‐mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels 2004 ·The Journal of Physiology ·Marzia Martina, (unknown), Samantha Halman, John Lowe, Pranav Periyalwar, Christopher J. Schmidt, Richard Bergeron	137
7	The Anxieties of Drug Discovery and Development 2002 ·Pharmaceutical biotechnology ·Franco Lombardo, Steven M. Winter, Larry M. Tremaine, John Lowe	0
8	Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception 1999 ·European Journal of Pharmacology ·(unknown), John Lowe, Sandra P. Welch	73
9	Characterization of Δ9-Tetrahydrocannabinol and Anandamide Antinociception in Nonarthritic and Arthritic Rats 1998 ·Pharmacology Biochemistry and Behavior ·Forrest L. Smith, Ken Fujimori, John Lowe, Sandra P. Welch	132
10	Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist 1998 ·Bioorganic & Medicinal Chemistry Letters ·Terry Rosen, Karen J. Coffman, Stafford McLean, (unknown), Dianne K. Bryce, (unknown), Megumi Tsuchiya, Atsushi Nagahisa, (unknown), John Lowe	28
11	Characterization of Non-peptide Antagonist and Peptide Agonist Binding Sites of the NK1 Receptor with Fluorescent Ligands 1997 ·Journal of Biological Chemistry ·Gerardo Turcatti, Sannah Zoffmann, John Lowe, Susan E. Drozda, Gérard Chassaing, Thue W. Schwartz, André Chollet	57
12	Follicular fluid levels of midazolam, fentanyl, and alfentanil during transvaginal oocyte retrieval† 1995 ·Fertility and Sterility* ·(unknown), Owen Boyd, Thanos Paraschos, Susan Duffy, S. BOWER, (unknown), John Lowe, Robert Michael Grounds	49
13	Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A 1995 ·European Journal of Pharmacology ·Mario D. Aceto, Susan M. Scates, John Lowe, Billy R. Martin	109
14	Assessing Health Risks Associated with DDT Residues in Soils in California: A Proposition 65 Case Study 1994 ·Risk Analysis ·John Lowe, Ijaz S. Jamall	1
15	5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists 1994 ·Journal of Medicinal Chemistry ·John Lowe, David Hageman, Susan E. Drozda, Stafford McLean, Dianne K. Bryce, (unknown), Stevin H. Zorn, Jean Morrone, Jon Bordner	62
16	Selective blockage of sensory response of the carotid body to hypoxia by NK-1 receptor antagonist CP-96,345 1993 ·Regulatory Peptides ·Nanduri R. Prabhakar, R. Michael Snider, John Lowe, Hailong Cao	2
17	Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist 1992 ·European Journal of Pharmacology ·Atsushi Nagahisa, Yoshihito Kanai, Osamu Suga, Kana Taniguchi, Megumi Tsuchiya, John Lowe, (unknown)	51
18	Young Children's Understanding of Counting and Cardinality 1989 ·Child Development ·Douglas Frye, (unknown), John Lowe, Celine Maroudas, (unknown)	89
19	The Education of Adults: A World Perspective. 1975 ·John Lowe	29
20	Knowledge and communication 1956 ·John Lowe	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact